Frontotemporal dementia (FTD) encompasses a group of neurodegenerative disorders characterized by progressive atrophy of the frontal and temporal lobes. The tauopathy-associated neurons in FTD represent a selectively vulnerable population that undergoes characteristic pathological changes, including hyperphosphorylated tau accumulation, neuronal dysfunction, and eventual cell death.
¶ Cell Markers and Molecular Signature
- Tau protein (MAPT) — microtubule-associated protein that aggregates into neurofibrillary tangles
- 3R and 4R tau isoforms — different splice variants with distinct pathological roles
- TDP-43 — RNA-binding protein aggregating in most FTD subtypes (except CBD/PSP)
- p62 — ubiquitin-binding protein marking tau and TDP-43 inclusions
- Vimentin — intermediate filament upregulating in degenerating neurons
The earliest and most severely affected population in FTD. These neurons project to the hippocampal formation and are critical for episodic memory. Their degeneration underlies the prominent early memory impairment in some FTD subtypes.
Large projection neurons in the frontal cortex that degenerate prominently in FTD. These neurons provide cortico-subcortical projections and their loss contributes to executive dysfunction and motor symptoms.
Large pyramidal neurons in layer V of the anterior cingulate and frontoinsular cortex. These selectively vulnerable neurons are particularly affected in FTD and may explain the early social and emotional dysregulation.
- Tau hyperphosphorylation — impaired microtubule function and tau mislocalization to dendrites
- Synaptic dysfunction — tau at synapses disrupts glutamatergic and GABAergic transmission
- Axonal transport defects — tau accumulation impairs mitochondrial and vesicle trafficking
- Endoplasmic reticulum stress — tau pathology triggers unfolded protein response
- Oxidative stress — mitochondrial dysfunction and increased reactive oxygen species
Tau pathology in FTD follows a predictable pattern:
- Entorhinal cortex → hippocampal formation
- Frontal cortex → parietal cortex
- Subcortical structures (basal ganglia, brainstem)
Unlike AD, FTD tauopathies often feature:
- Earlier onset (45-65 years)
- Prominent behavioral changes
- Less hippocampal memory impairment early
- Different regional distribution (frontal > medial temporal)
- Anti-tau antibodies — ongoing trials for monoclonal antibodies (gosuranemab, tilavonemab)
- Tau aggregation inhibitors — Methylene Blue derivatives show mixed results
- Microtubule stabilizers — Davunetide failed in clinical trials
- Gene therapy — ASO targeting MAPT mRNA under investigation
- Dickson et al., Neurodegeneration: The Molecular Pathology of FTD (2010)
- Rohrer et al., FTD Classification and Clinical Features (2011)
- Spillantini & Goedert, Tau Protein Pathology in FTD (2013)
- Seeley et al., Neurodegeneration Patterns in FTD (2009)